01 jun: UPDATE: FTC Says Graco Must Sell Illinois Tool's Finishi..
01 jun: Canada's Senate Passes Back-To-Work Bill To End CP Rail ..
01-06-2012 00:14:00

UK Regulator Draft Guidance Recommends Bayer's Xarelto For Blood Clots

Relateret indhold
Relateret debat
01 sep - 
Dear Sir/Ma, We have direct providers of Fresh Cut BG, ..
01 sep - 
We are direct provider for BG/SBLC specifically for lea..
01 sep - 
We are direct provider for BG/SBLC specifically for lea..

FRANKFURT -(Dow Jones)- The U.K. drug regulator has recommended the use of Xarelto, a drug produced by a unit of Bayer AG (BAYN.XE), to treat blood clots, according to draft final guidance published Friday.

The guidance is likely to result in a recommendation from the National Institute for Health and Clinical Excellence, known as NICE, meaning the U.K. public health-care system will offer the drug and pay for it. The draft guidance is now with consultees, who have the opportunity to appeal against it.

"Bayer Healthcare welcomes this draft final appraisal determination recommendation from NICE because it simplifies the treatment of venous blood clot treatment for physicians and their patients," Bayer spokeswoman Astrid Kranz said.

Earlier, NICE had asked Bayer to provide more information on the drug. The move follows a May 22 approval for Xarelto for stroke prevention and systemic embolism in people with atrial fibrillation.

If the final approval is given, Xarelto, also known as Rivaroxaban, may then be offered as an alternative to injectable anticoagulants such as low-molecular-weight heparin or fondaparinux sodium, overlapped with a vitamin-K antagonist, such as warfarin.

It is estimated that there will be over 46,000 cases of acute deep vein thrombosis, or DVT, in England and Wales during 2012, rising to nearly 50,000 by 2016 due in large part to the aging population, NICE said.

"Xarelto is the first only novel oral anticoagulant offering a unique single drug solution for the treatment of DVT in adults," Kranz said.

On May 24, Bayer confirmed it expects peak sales of Xarelto of above EUR2 billion annually. The drug, which is being co-developed by Bayer and U.S. drug maker Johnson & Johnson (JNJ), is a rival of Boehringer Ingelheim GmbH's Pradaxa.

-By Monica Houston-Waesch, Dow Jones Newswires; +49 69 29 725 504; nikki.houston@dowjones.com

(END) Dow Jones Newswires

May 31, 2012 18:14 ET (22:14 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Novo: Nygodkendt diabetesmiddel giver lynhurtigt effekt

19-09-2014 11:31:02
Novo Nordisks nye kombinationspræparat til behandling af type 2 diabetes, Xultophy, yder allerede efter fire uger en betydelig blodsukkerkontrol.Det fremgår af ..

Aktier/tendens: Skotsk afstemning løfter stemningen

19-09-2014 08:33:40
De europæiske aktiebørser, og i særdeleshed det britiske marked, ventes fredag at åbne med stigninger, efter at Skotland torsdag stemte nej til en løsrivelse fr..

Vind/WWEA: Vindmøllerne vandt frem i første halvår

18-09-2014 16:26:41
Den samlede installerede vindkraftkapacitet voksede med 5,5 pct. i første halvår af 2014, viser en rapport fra brancheforeningen World Wind Energy Association (..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Torsdagens aktier: Tre storaktier trak rekorder i land
2
Vestas/Jyske: Svagt momentum bag lavere kursmål
3
Aktier/åbning: C20 styrer mod rekord efter skotsk afstemning
4
Vind/WWEA: Vindmøllerne vandt frem i første halvår
5
Novo får godkendt kombinationsmidlet Ideglira i EU

Relaterede aktiekurser

Johnson & Johnson 107,35 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. september 2014 13:48:59
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140919.1 - EUROWEB1 - 2014-09-19 13:48:59 - 2014-09-19 13:48:59 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x